SERPASIL Drug Patent Profile
✉ Email this page to a colleague
When do Serpasil patents expire, and when can generic versions of Serpasil launch?
Serpasil is a drug marketed by Novartis and is included in four NDAs.
The generic ingredient in SERPASIL is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SERPASIL?
- What are the global sales for SERPASIL?
- What is Average Wholesale Price for SERPASIL?
Summary for SERPASIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Patent Applications: | 1,213 |
| DailyMed Link: | SERPASIL at DailyMed |
US Patents and Regulatory Information for SERPASIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SERPASIL | reserpine | ELIXIR;ORAL | 009115-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | SERPASIL-APRESOLINE | hydralazine hydrochloride; reserpine | TABLET;ORAL | 009296-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | SERPASIL | reserpine | TABLET;ORAL | 009115-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
